United States v. Kosinski, No. 18-3065 (2d Cir. 2020)Annotate this Case
The Second Circuit affirmed defendant's conviction of two counts of insider trading in violation of Section 10(b) of the Securities Exchange Act of 1934, and Rule 10b–5. The court held that defendant had a duty to refrain from trading on nonpublic inside information and that the evidence was sufficient to convict him. In this case, defendant served as a principal investigator for a clinical trial of a cardiac drug developed by Regado Biosciences, a publicly traded biopharmaceutical company, that was designed to prevent blood clotting. After defendant learned that patients suffered adverse effects during the trial, he traded on that nonpublic inside information to avoid a loss and earn a profit in the shares of the company. The court concluded that, taken together, the evidence of defendant's deceptive activity was sufficient for the jury to find that he was a sophisticated investor that knew his actions were unlawful under the charge given by the district court. Finally, there was no abuse of discretion in the district court's evidentiary rulings.